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Abstract
The potent clinical responses seen in patients with chronic myeloid leukemia (CML) after
administration of donor-specific lymphocytes, as well as the correlation between the presence of
antigen specific T cells and prolonged remission in these patients, suggests a role for the
immunological control of CML. Here we propose Aldara™, a clinically used formulation of
imiquimod, as an agent for augmenting immune responses to CML antigens. Our proposition is
based upon 3 tenets: 1) Endogenous dendritic cells (DC) of CML patients, which are known to be
derived from the malignant clone, express and present various leukemic antigens; 2) CML-antigen
reactive T cell clones exist in the patient but in many situations are ineffectively stimulated to cause
significant hematological responses; and 3) Antigen presentation by mature, activated DC, which
endogenously express CML-antigens may endow the pre-existing ineffective T cell responses with
ability to control CML progression. The practical use of Aldara™ as a localized activator of DC in
the context of present day leukemic therapeutics, as well as various properties of this unique
immune modulator will be discussed.
Background
Chronic myeloid leukemia (CML) is a myeloproliferative
disease characterized by an indolent chronic phase during
which immature myeloid cells increase in the peripheral
blood and bone marrow, followed by an accelerated
phase, associated with resistance to standard therapies,
and terminates in blast crisis where undifferentiated blasts
damage vital organs, leading in death. Treatment of CML
has undergone several major advancements: a) The devel-
opment of chemotherapeutic interventions such as busul-
phan and 6-thioguanine in 1953; b) The introduction of
alpha interferon in 1983; c) Bone marrow transplantation
in 1986; and d) BCR-ABL-specific tyrosine kinase inhibi-
tors in 1998 [1]. Therapeutic interventions for CML aim to
accomplish three goals: to achieve a hematologic remis-
sion (normalization of leukocyte numbers), to achieve
cytogenetic remission (0% Ph-positive cells on chromo-
somal analysis), and, to achieve molecular remission
(negative PCR result for the BCR-ABL fusion transcript)
[2]. The current standard of care for CML patients is
administration of imatinib, a selective inhibitor of BCR-
ABL, or allogeneic stem cell transplantation [3]. Although
imatinib induces hematological and sometimes even
cytogenetic remission in the accelerated phase [4] and in
myeloid blast crisis [5], these remissions are often short-
lived, due in part to the ability of the CML cells to mutate.
In a study where imatinib-treated patients were followed
for 4.5 years, it was reported that hematologic resistance
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occurred in 25%, 41%, and 92% of patients in CP, AP,
and myeloid BC, respectively, and was associated with
BCR-ABL mutations in 45% of patients [6]. Generally,
resistance to imatinib is associated with mutations in the
ATP-binding pocket of the BCR-ABL kinase, and also with
several other factors: 1) Amplification of the BCR-ABL
transcript [7]; 2) Expression of drug efflux proteins such as
P-glycoprotein [8]; and 3) Increased plasma concentra-
tions of the imatinib binding protein, alpha -1 acid glyco-
protein [9]. In light of these limitations, as well as the fact
that only a small subset of patients are eligible for bone
marrow transplantation, strong incentive exists for devel-
opment of novel approaches to CML therapy.
Immunogenicity of CML: The Adaptive Immune 
Response
The concept that leukemic cells are immunogenic was
introduced in the 1960s when Mathe's group demon-
strated a survival advantage in acute lymphocytic leuke-
mia (ALL) patients that were treated with irradiated
allogeneic blast cells together with BCG and chemother-
apy, in comparison to patients receiving chemotherapy
alone [10]. Similarly, in a 1975 study of 50 acute myelo-
cytic leukemia (AML) patients induced into remission,
those receiving irradiated allogeneic blasts together with
BCG in combination with chemotherapy had an average
survival of 510 days compared to patients receiving chem-
otherapy alone who had an average survival of 270 days
[11]. Despite these positive results, immunotherapy fell
out of favor when a meta-analysis of 24 trials concluded
no clinically relevant benefit in 1983 [12]. Immunogenic-
ity of CML cells was supported by reports of antibody [13]
and T cell proliferative [14] responses in CML patients
after administration of irradiated allogeneic cells together
with immunological adjuvants. Furthermore, administra-
tion of purified IgG antibodies from goats immunized
with the human CML cell line K562 in two CML patients
led to a sharp decrease and the eventual eradication of
blasts from the peripheral blood and bone marrow [15].
Although this therapeutic option cannot be advocated
due to the potential for induction of serum sickness, it
does suggest the existence of CML-specific antigens.
Molecular evidence for the existence of CML-specific T cell
responses was brought forward by Cheever et al who dem-
onstrated that CD4 T cell immunity could be generated
toward BCR-ABL expressing cell lines after vaccination of
mice with peptides generated from the junctional region
of the BCR-ABL fusion protein [16]. Indeed, the identifi-
cation of HLA class I [17], and HLA class II- binding [18]
BCR-ABL peptides supports the hypothesis that antigen
presentation, and subsequent T cell recognition of this
specific oncoprotein may serve as a mechanism for the
graft versus leukemia (GVL) effect commonly seen in
bone marrow transplant patients. These studies also dem-
onstrated that presentation of BCR-ABL peptides is medi-
ated only by specific HLA haplotypes. Since patients
lacking such haplotypes also can mount a GVL response,
it is clear that BCR-ABL peptides are not the only antigens
involved. However, there exists an epidemiological corre-
lation between patients having the same HLA-haplotypes
that are known to bind the BCR-ABL peptides, such as
HLA-A3, HLA-B8, and HLA-DR4, and resistance to devel-
oping CML [19-21]. The identity of other peptides that are
presented by these alleles in the context of CML is still
under investigation.
Utilization of synthetic peptides corresponding to the
BCR-ABL junctional areas as immunogens has been per-
formed by numerous groups to activate both CD4 and
CD8 T cells from healthy donors [17,18,22]. Interestingly,
in vitro generated CD4+ T cells specific to BCR-ABL
immunogenic peptides were shown to proliferate and
produce Th1 cytokines in response to HLA-matched CML
blasts in absence of exogenous antigen presenting cells
[23]. This finding complements another report that CML
progenitor cells are CD34+ MHC II+ and can directly
present antigens to T cells [24]. A fundamental question is
whether T cells from CML patients under natural condi-
tions can recognize BCR-ABL antigens, or whether
through a mechanism of tumor-induced tolerance, these
cells are anergized or deleted, as occurs in melanoma [25].
Indeed, T cell anergy has been reported in a series of exper-
iments involving the stimulation of lymphocytes with
autologous CML cells [26]. Functional escape from unre-
sponsiveness was demonstrated by incubation of the cul-
tures with IL-2. When precursor frequencies were
evaluated, it was determined that a much lower number
of CML-specific CD8 T cells (1:38,000) was observed in
comparison to CD4 cells (1:4,000). Whether this is a
result of preferential induction of apoptosis in CD8 cells
or whether CD4 cells are capable of inducing effective
CML-inhibitory responses is not known. However, in the
context of bone marrow transplantation (BMT), it is
known that CD8-depleted donor lymphocyte infusion is
as effective as non-depleted lymphocytes at inducing
remission in post BMT relapse [27], therefore it appears
that at least in some systems, CD4+ cells specific for leuke-
mic antigens may be therapeutically beneficial.
While the concept of generating CML-specific T cells is
appealing, the question of why such T cells don't naturally
control CML arises. As previously mentioned, it appears
that there is a functional incapacitation of leukemic-spe-
cific T cells in patients. Reports of T cell anergy in CML
patients to specific leukemia-associated antigens have
included the demonstration of an inability to raise BCR-
ABL-targeting T cells from PBMCs derived from CML but
not healthy volunteers [28], as well as the reduction in
number of T cells specific for the CML antigen PR1 inJournal of Translational Medicine 2007, 5:4 http://www.translational-medicine.com/content/5/1/4
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interferon non-responding patients [29]. These observa-
tions raise the question if the T cells exist in a state of
anergy from which they can be rescued by immune stim-
ulation, or whether they are ablated by central tolerance
or peripheral apoptosis. Evidence seems to point to the
former rather than the latter. Specifically, administration
of IFN-alpha to patients has been demonstrated to
induce/restore ability of BCR-ABL peptide specific T cells
to produce Th1 cytokines, as well as to endow them with
cytotoxic activity [30]. When looking at the second well-
known CML-specific antigen PR-1, it was demonstrated
that patients entering cytogenetic remission through
administration of IFN-alpha also had a re-emergence of
high-affinity antigen-specific CD8 cells with potent cyto-
lytic activity in vitro [31].
From these studies it appears that not only is T cell immu-
nity possible to CML cells, but such immunity appears to
be relevant to clinical outcome. The fact that antigen-spe-
cific suppression of anti-CML responses occurs [28,31]
but can be reversed by appropriate immune stimulation
provides impetus for studies investigating immune mod-
ulatory therapies for CML.
Immunogenicity of CML: The Innate Immune 
Response
In recent years the molecular identification of mecha-
nisms associated with innate recognition of "danger" sig-
nals has led to a rebirth of the study of innate immunity.
Specifically, the discovery of the toll-like receptors (TLRs)
as well as other "sensors of danger" such as the nucle-
otide-binding oligomerization domain (NOD)-contain-
ing proteins has stimulated a plethora of studies assessing
the role of innate immune components in areas not tradi-
tionally associated with immunology. For example, TLRs
have been shown to play a critical role in situations rang-
ing from ischemia-reperfusion injury [32], to heart failure
[33], and tumor regression [34]. In terms of CML, it is
known that various innate immune cells such as macro-
phages [35] and NK cells are capable of spontaneously lys-
ing leukemic cells. As a matter of fact, the classically used
cytotoxicity assay for determination of NK activity
involves using the CML blast crisis-derived cell line K562
as a target [36].
NK cells lyse targets that possess low or absent levels of
MHC class I molecules [37]. This concept was termed the
"missing self" hypothesis and was molecularly demon-
strated by the fact that NK cells possess inhibitory recep-
tors that transduce a negative signal upon ligation of MHC
alleles [38]. Therefore, the NK cell is thought to act as a
"back-up" mechanism of immune surveillance against
neoplasia: Specifically, tumors which lose MHC expres-
sion in order to evade T cell mediated immune attack can
not escape since the loss of MHC will sensitize them to
killing by NK cells. The problem with this hypothesis was
that certain cell types such as erythrocytes do not express
MHC but are not target of NK lysis. To deal with this, acti-
vatory receptors were subsequently discovered on NK cells
such as NKG2D whose ligand is MICA, a distant homolog
of major histocompatibility complex (MHC) class I whose
expression is associated with neoplasia, infection or sub-
lethal cellular damage [39]. The important role of NKG2D
in immune surveillance was demonstrated in studies
where the neutralization of NKG2D resulted in enhanced
incidence of spontaneous tumor formation in a murine
model [40]. MICA expression is associated not only with
cellular stress but also with DNA damage and activation of
DNA-repair proteins such as ATR, ATM or Chk1 [41], pro-
teins which are chronically activated during the process of
carcinogenesis [42]. In respect to CML, CD34+ cells from
patients but not from healthy volunteers were demon-
strated to expressive high levels of MICA and MICB, which
was associated with activation of NKG2D and lysis by NK
cells [43]. Supporting the role of MICA in CML are studies
that demonstrated that transfection of various cells with
BCR-ABL actually increases the concentration of MICA
[44]. This upregulation of MICA correlated with ability of
the transfected cells to activate NK cells to proliferate, pro-
duce IFN-γ, as well as lyse BCR-ABL expressing cells.
The role of NK cells in CML is very interesting. One reason
is that NK cells are found naturally residing in the bone
marrow and affect hematopoiesis through secretion of
stimulatory factors such as GM-CSF [45], as well as their
ability to produce TNF-α and IFN-γ [46], which inhibit
hematopoiesis. The functional activity of NK cells to alter
hematopoiesis was demonstrated in an experiment where
the transfer of activated NK cells with bone marrow pro-
genitors into lethally irradiated syngeneic mice resulted in
greater engraftment in the recipients in comparison to
mice receiving bone marrow and control cells [47]. In
light of the fact that IL-2 activated NK cells have been
demonstrated to specifically lyse not only CML cell lines
but also primary blasts [48], and the observation that acti-
vated NK cells home into the bone marrow [49], the ther-
apeutic possibilities of this cell population have attracted
much investigation in CML.
Ex vivo activation of NK cells by IL-2 was performed in
bone marrow cultures as a method of "purging" AML cells
from the non-malignant marrow for use in autologous
bone marrow transplant resulting in clinical remission in
a subset of patient [50]. Additionally, the NK cell line NK-
92 was generated under good manufacturing practices
with the purpose of ex vivo purging of CML cells for
autografts due to its selective ability to lyse leukemic pro-
genitors [51]. In terms of in vivo administration of acti-
vated NK cells, to our knowledge no studies have been
conducted in CML patients, however use of NK stimulat-Journal of Translational Medicine 2007, 5:4 http://www.translational-medicine.com/content/5/1/4
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ing agents such as IL-2 [52,53], and roquinimex [54], has
been performed with some clinical benefit, although at
present these therapies have not been optimized. Despite
this, the clinical relevance of NK cells in CML should not
be underestimated. Early studies have demonstrated that
peripheral blood CD56+, CD16+ NK cells derived from
CML patients were inferior to cells purified of a similar
phenotype from healthy controls in terms of cytotoxic
activity towards K-562 cells, as well as IFN-γ and IL-1 pro-
duction in response to PHA [55]. More recent studies have
shown that CML patients who respond to interferon [56]
or other immune modulatory therapies such as heat shock
protein vaccination generally have higher CD56+, CD16+
NK cell mediated cytotoxic activity towards K562 cells as
compared to treatment non-responders [57]. An interest-
ing observation is that as a last-ditch effort by the immune
system to preserve the host, NK cell activity in blast crisis
phase of CML is reported to be increased in comparison to
healthy controls [58]. A practical explanation may be that
the high concentrations of circulating NK activatory com-
pounds may be systemically activating the NK cells.
In conclusion, while the effector innate immune system
definitely is involved in the control of CML, little work has
been performed in this area. The essential role of cells like
DC and NK in terms of shaping the T cell response is only
now beginning to be elucidated. Future studies integrating
the activation of both the innate and adaptive immune
responses will lead to development of novel therapeutics.
What follows is a hypothesis of a novel way of harnessing
the innate and adaptive immune responses through the
use of a clinically available agent, Aldara™.
Aldara™ as an Immune Stimulant
The active ingredient in Aldara™ is imiquimod, a low
molecular weight immune stimulant. Previous to devel-
opment of Aldara™ as a topical form of imiquimod, oral
imiquimod has been assessed clinically for immune stim-
ulatory effects both in cancer and HIV patients in the
1990s. These studies have demonstrated an unacceptable
benefit/toxicity profile and as a result administration via
the topical route was chosen for development. Specifi-
cally, Goldstein et al reported a Phase I study involved 12
patients with HIV infection that were dose escalated by
100 mg/week until toxicity was reached. When toxicity
was reached, maintenance dosing of 100 mg/week lower
than the toxic dose was performed. Dose-limiting toxicity
occurred in 3 patients at 200-mg, 5 at 300-mg, and 3 at
400-mg dose levels. One patient tolerated the 500-mg
dose without dose-limiting toxicity. While 7 of the 12
patients completed the 12 week dosing schedule, no con-
sistent effect on viral load was observed. Importantly,
serum interferon alpha was observed to rise, as well as
neopterin and beta2-microglobulin, which are markers of
immune activation [59]. In cancer therapy, Witt et al
observed no clinical responses in 14 patients receiving
100–500 mg of imiquimod on a once or twice weekly
basis. In agreement with the HIV study, dose limiting tox-
icities were observed between 300–500 mg week, and
serum markers of immune activation were elevated. The
authors concluded that before Phase II trials begin, estab-
lishment of a consistent tolerated dose and administra-
tion schedule is needed [60]. Savage et al used daily oral
treatment of 25–200 mg of imiquimod in patients with
refractory cancers. Of 21 patients in the study, one patient
had a partial clinical response in disease stabilization.
Only three of the 21 patient completed the scheduled
treatment course of 112 days. These patients received the
50 mg/day dose, all other patients dropped out due to tox-
icity, death, or personal reasons. The authors concluded
that although elevation in plasma markers of immune
activation were observed, the treatment schedule used
needed to be modified due to high levels of toxicity [61].
Given the impracticality of using systemic oral imiqui-
mod therapy, the topical form of imiquimod was devel-
oped for dermatological uses under the name Aldara™.
Aldara™ is a formulation of 5% imiquimod in an oil-in
water vanishing cream base that is approved for use in the
United States for treatment of actinic keratosis, superficial
basal cell carcinoma and external genital warts [62].
Aldara™ is supplied in single-use packets of 250 mg of
cream, of which are applied 2–5 times per week depend-
ing on indication. Specifically, for treatment of actinic
keratosis (AK), a premalignant dysplasia of the epidermis
associated with UV exposure, Aldara™ is applied on a
twice-weekly basis to a 25-cm2 treatment area surround-
ing the lesion on the face or scalp for no more than 16
weeks. In two pivotal studies submitted for FDA-registra-
tion, of a total of 215 actinic keratosis patients treated as
described, 97 patients had complete resolution of lesions.
This is in contrast to the 221 patients receiving placebo
cream in which only 7 patients reported clearance of
lesions [62]. Of the 185 patients with superficial basal cell
carcinoma treated with Aldara™ in the FDA pivotal trial
complete responses were observed in 139 patients,
whereas of 179 patients treated with control only three
patients responded. The treatment scheme for this study,
which is in clinical use today, involves topical administra-
tion of 250 mg of cream for 5 days a week for the period
of 6 weeks (62). The third accepted indication, external
genital warts, was approved based on a trial of 109 treated
patients, of which 54 had complete clearance, whereas of
the 100 patients treated with vehicle control only 11 had
clearance. The accepted treatment schedule involves 3
times per week topical treatment for a maximum of 16
weeks [62].
In addition to the above date, subsequent data supporting
effectiveness of Aldara™ for the above indications wereJournal of Translational Medicine 2007, 5:4 http://www.translational-medicine.com/content/5/1/4
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reported. For example, Lee et al examined 146 AK patients
which were administered Aldara™ either 2 or 3 times per
week for a period of 16 weeks. Recurrence of AK lesions
was observed in only 24.7% (19 of 77) of the patients on
the 3 times per week regimen and in 42.6% (23 of 54) of
the patients on the 2 times per week regimen. With excep-
tion to localized irritation, no adverse effects were
reported in any of the patients in this 30 center study [63].
The importance of immune modulation was also
observed in patients receiving Aldara™ for this indication
in that another study demonstrated lesional infiltration of
CD11c+ dendritic cells, as well as both CD4 and CD8 T
cells in AK patients responding to Aldara™ on the 3 times
per week regimen [64]. In a study evaluating long-term
responses of superficial basal cell carcinoma patients to
Aldara™ treatment, 169 patients were treated using the
currently accepted 5 days a week, for the period of 6
weeks, schedule. On average, the clearance rate at 12
weeks post completion of treatment was 94.1%, and at
the 2-year follow-up was 82.0% [65]. Results in the treat-
ment of genital warts have also reproducing the initial
findings in the pivotal studies. For example, Arican et al
reported a double blind study treating 34 patients on the
accepted 3 times a day for 12 weeks regimen. Of these, 23
patients achieved complete clearance of the treated warts,
whereas only 1 out of the 11 patients who received pla-
cebo cream had wart clearance [66]. Collectively, these
studies attest to the reproducibility of the clinical rele-
vance of this topical immunomodulatory agent in a vari-
ety of dermatological settings.
Although the first FDA approval for use of Aldara™
occurred in 1997, the molecular mechanism of action was
only identified five years later in 2002 by Hemmi et al,
who demonstrated that active ingredient, imiquimod, is a
stimulator of the toll-like receptor 7 (TLR7)-MyD88-
dependent signaling pathway on immune cells [67].
Other stimulators of TLR-7 are known such as isatoribine
[68] and resiquimod [69] although a discussion of these
compounds is outside of the scope of this review. Original
analysis of TLR-7 expression revealed pulmonary, placen-
tal and splenic tissues as high expressers [70]. At a cellular
level it was observed that the primary interferon alpha
producing cell, the plasmacytoid DC, responds to treat-
ment with imiquimod by upregulating the lymphoid
homing receptor CCR-7, enhancing expression of costim-
ulatory molecules, as well as producing large amounts of
interferon alpha [71]. In the mouse, plasmacytoid DC
found in the skin are positive for CD4, GR-1, B220, and
MHC class II. These cells are found in the skin of healthy
mice, and dermal interferon response to imiquimod cor-
relates with amount of these cells in the skin [72]. In
humans treated with Aldara™, regardless of whether treat-
ment is for superficial basal cell carcinoma, Bowden's dis-
ease, or cutaneous T cell lymphoma, all patients develop
an increase in local plasmacytoid DC having the pheno-
type CD123+ and BDCA-2+ and associated with a specific
cytokine signature [73]. The authors of the study reported
that these cells are found in small quantities in healthy
volunteers, supporting previous studies also describing
plasmacytoid DC at the border between the basement
membrane and dermis [74].
The importance of these DC in priming of immune
responses subsequent to imiquimod administration was
demonstrated in experiments applying a combination of
imiquimod and antigen epicutaneously. This type of
"trans-immunization" was able to elicit potent cytotoxic T
cell responses through the activation of both plasmacy-
toid, and myeloid-derived DC in a murine model [75].
Although some in the field believe that the murine system
possesses certain peculiarities that may not allow direct
comparison with results in human studies, an interplay
between the plasmacytoid DC and the activation of
immature myeloid DC was demonstrated in individuals
administered Aldara™ cream. The immature myeloid DC
administered to Aldara™ -treated subjects migrated faster
and more efficiently to draining lymph nodes than
mature myeloid DC and control treated immature mye-
loid DC [76].
In terms of its clinical use, an immunological mechanism
is believed responsible, especially in cases of virally-
induced genital warts since imiquimod itself is not active
against viruses in the absence of a functional immune sys-
tem [77]. Indeed, patients with genital warts, which
exhibit high responsiveness to Aldara™, often display a
higher level of plasmacytoid DC activation, as judged by
expression of HLA-DR than non-responders [77]. On the
T cell side, an increased number and level of IFN-γ pro-
duction is associated with response in patients with
intraepithelial neoplasia [78]. Overall, the antiviral and
anti-neoplastic/preneoplastic activities of imiquimod are
believe to work according to the following steps: a) Initial
activation of low level pro-inflammatory cytokine secre-
tion by resident macrophages and local plasmacytoid DC;
b) Chemoattraction of additional plasmacytoid DC from
circulation; c) Migration of Langerhans cells to draining
lymph nodes/NK production of IL-12, and d) Increased
presentation of antigen from DC, resulting in T cell activa-
tion [79].
In summary, Aldara™ has been demonstrated to induce
various molecular and cellular changes that evoke clinical
responses against various viral and preneoplastic/neoplas-
tic conditions. For the remainder of the manuscript we
will discuss the therapeutic possibility of medication in
regards to CML.Journal of Translational Medicine 2007, 5:4 http://www.translational-medicine.com/content/5/1/4
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Aldara™ Stimulation of CML-Specific Responses
CML is a unique disease from the perspective of the tumor
immunologist. Since the leukemic clone differentiates
into all cells of the myeloid lineage, the majority of DC
isolated from CML patients direct progeny of the leukemic
stem cell. It is established that in CML patients, DC can
not only present the leukemia specific BCR-ABL peptides,
but also that such presentation can lead to generation of
antigen-specific T-cells capable of inducing lysis of CD34
cells from CML but not control patients in an MHC-I
dependent manner. Indeed, CML is different than almost
any other cancer in that DC immunotherapy would not
require the pulsing of DC with exogenous antigens, since
CML DC endogenously express BCR-ABL immunogenic
peptides at sufficient concentrations to stimulate a T cell
response [80]. This concept has been demonstrated clini-
cally through the use of GM-CSF administration to
expand endogenous DC numbers followed by donor lym-
phocyte infusion, resulting in a positive impact on patient
survival that was associated with increased anti-leukemic
response [81], which was believed to be due to enhanced
presentation of leukemic antigens from DC. However the
treatment proposed here is less "invasive" and more appli-
cable to widespread implementation.
The proposition of this paper is that topical administra-
tion of Aldara™ would induce the differentiation and
expansion of CML DC at the cutaneous sites of adminis-
tration. This differentiation would then lead to upregu-
lated expression of MHC I and II bearing leukemic
peptides, costimulatory molecules, as well as interferon
alpha production, in a milieu that would not only rescue
the CML-specific T cells from anergy, but also induce their
proliferation, expansion, and acquisition of cytotoxic/
leukemia inhibitory function. Several questions arise...
First, will the DC that are activated by Aldara™ treatment
actually express BCR-ABL peptides? Some believe that
plasmacytoid DC are only derived from lymphoid lineage
and thus will be BCR-ABL negative. To this question we
respond by stating the main anti-CML effect of the
Aldara™ treatment will not be through the direct activa-
tion of the plasmacytoid DC, but through the indirect acti-
vation of the myeloid derived DC that occurs as a result of
the immune stimulation. For example it was demon-
strated that not only does Aldara™ treatment potently
induce maturation of myeloid DC through indirect effects
[82], but also that local treatment induces migration of
such cells to spleen, where in conjunction with NKT cell
activation results in induction of systemic immune mod-
ulation capable of promoting antigen-specific immunity
in a melanoma model [83]. Therefore we anticipate that
the activation of myeloid DC will induce an increased
presentation of anti-leukemic T effector cells. Addition-
ally, the known effects of Aldara™ in activating NK cell
function are also postulated to contribute to anti-leuke-
mic effect [84].
Second, will the CML-specific T cells not be anergized in
vivo, such that even if the presentation of BCR-ABL pep-
tides does occur, the T cells will not be able to mount a
productive anti-leukemic response? Although it was previ-
ously stated that anergy to CML-specific T cells occurs in
CML patients, this anergy seems reversible either by addi-
tion of cytokines or antigen-specific vaccination. The
recent reports of hematologic and cytogenetic remissions
induced by immunization with BCR-ABL peptides sup-
port this notion. Interestingly it was observed that higher
antigen-specific responses occur in patients that are con-
currently receiving interferon alpha [85-87]. These obser-
vations suggest that T cell clones specific for CML may
indeed by reactivated in vivo, in a similar manner to how
ex vivo IL-2 treatment of T cells induces escape from
anergy [88]. Indeed imiquimod has been demonstrated to
increase expression of CD80 and CD86, which are
involved in escape from anergy [89,90], as well as upreg-
ulate production of IL-12 [91] which inhibits IL-10 gener-
ation [92], known to be responsible for maintaining the
anergic state [93]. Along these lines, it is reported that
upregulation of costimulatory molecules on circulating
tumor cells in CLL patients following topical administra-
tion of imiquimod occurs, thus supporting the possibility
that local administration of this agent may have systemic
effects [94].
Third, what about CML specific antigens that are not
expressed endogenously in DC of CML patients? Specifi-
cally, antigens such as telomerase [95], PR1 [29], PASD1
[96], CML28 and 66 [97] have not been identified in CML
derived DC although immune responses to these have
been observed in patients. To this we first answer that
healthy, non-leukemic derived DC should theoretically
engulf and present antigens derived from leukemic cells
due to their "immunological sentinel" role. Therefore the
activation of DC will allow, to some extent, presentation
of leukemic antigens that are non-endogenous to the DC.
Secondly, we argue that although numerous CML anti-
gens exist that would not be present in leukemia-derived
DC, BCR-ABL, which is present, is known to be clinically
relevant based on responses observed in patients immu-
nized with BCR-ABL-derived peptides [17,87]. Thirdly, we
believe that the general immunostimulatory activity of
imiquimod will assist the immune response in "de-aner-
gizing" itself towards relevant antigens. For example it is
known that CML patients have lower NK cell activity in
comparison to healthy controls [55], and that clinical
response to immunotherapy is associated with enhanced
NK activity [56,57], therefore the NK stimulatory activity
of Aldara™ therapy may in fact actually mediate enhanced
anti-CML NK activity. An interesting but undevelopedJournal of Translational Medicine 2007, 5:4 http://www.translational-medicine.com/content/5/1/4
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area would be the effect of imiquimod on the immune
suppressive CD4+ CD25+ T regulatory cell population.
These cells mediate inhibition of T cell activation and
effector function both locally and systemically [98], and
are responsible for the blunted immune response to
numerous malignancies [99-102]. Antileukemic immune
therapies are enhanced by depletion of this cell popula-
tion [103,104]. Recently it was demonstrated that TLR
agonists function to render T cells unresponsive to the
suppressive effects of T regulatory cells [105], as well as
actually inhibiting the ability of T regulatory cells to sup-
press immune responses, and anti-tumor immunity
[106]. Although it is unlikely that plasma levels of imiqui-
mod are able to systemically derepress immunity by
inhibiting CD4+ CD25+ T cell functions, the effects at the
local site of administration may be interesting to examine.
The Clinical Implementation
How will Aldara™ administration be optimally used clini-
cally? In the ideal situation, Aldara™ would be adminis-
tered as maintenance therapy after induction of molecular
remission using bone marrow transplant, IFN-alpha or
imatinib. The low cost and tolerability of Aldara™ would
make this an interesting immunostimulating adjuvant.
Another situation where this therapy may be useful is
patients whom are non-responsive to imatinib and can-
not tolerate the effects of INF-alpha. Yet another embodi-
ment of this therapy would be application to the skin area
where CML-specific vaccines are administered, however, it
has been demonstrated that the vaccine stimulating effects
do not necessarily require local administration [83],
although this is controversial since it has only been dem-
onstrated in mice. Dosage could begin based on the stand-
ard protocol for superficial basal cell carcinoma of 5 times
per week on a 25 cm2 area of skin. Monitoring of therapy
would most likely involve ex vivo analysis of cytokine pro-
duction, as well as in more advanced clinical research set-
tings tetramer analysis for BCR-ABL specific T cells.
A potential concern for clinical implementation of
Aldara™ treatment for CML may be the possibility of acti-
vation of immunity that targets not only hematopoietic
stem cells of leukemic origin, but also non-leukemic
hematopoietic stem cells. Indeed the graft versus leukemia
effect observed after donor lymphocyte infusions is corre-
lated with a period of aplasia in which normal hemat-
opoietic stem cells are also targeted [107]. This is in
agreement with other studies of immune stimulation to
cancer antigens in which autoimmunity arises as an unin-
tended adverse event [108]. Given that Aldara™ treatment
as used clinically today is not associated with induction
autoimmunity towards hematological targets, the authors
do not anticipate this to be a major concern, however the
experimental use of Aldara™ in CML patients will need to
be monitored by hematological assessment to ensure that
CML-directed responses do not crossreact with non-
malignant progenitor cells.
Conclusion
We present a novel hypothesis that administration of the
topical TLR-7 agonist imiquimod in the form of Aldara™
may be a useful immunotherapy/adjuvant therapy for
CML patients with minimal residual disease. Thus a scien-
tific basis for utilization of this generally innocuous med-
ication is proposed for a lethal disease. Although the
current concept may require various modifications before
clinical entry, we put forth this idea as a stepping stone for
other investigators to expand upon. The lack of significant
toxicity and widespread use of this medication makes this
hypothesis attractive for testing. Present day therapies for
imatinib-resistant, IFN-alpha non-eligible, CML patients
are limited to maintenance therapy on hydroxyurea or
busulfan. The administration of Aldara™ to this patient
subgroup may provide a novel means of life extension
without drawbacks of severe myeloablative protocols.
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